Schisandrin B alleviates angiotensin II-induced cardiac inflammatory remodeling by inhibiting the recruitment of MyD88 to TLRs in mouse cardiomyocytes
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112660 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Sujing Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Joint Research Center on Medicine, the Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo 315700, China; Institute of Stomatology, S…. Hauptthemen laut MEDLINE: Cyclooctanes, Lignans, Myeloid Differentiation Factor 88, Polycyclic Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Russian Science Foundation.
Abstract (Originalsprache)
Cardiac tissue remodeling is characterized by altered heart tissue architecture and dysfunction, leading to heart failure. Sustained activation of the renin-angiotensin-aldosterone system (RAAS) greatly promotes the development of myocardial remodeling. Angiotensin II (Ang II), which is the major component of RAAS, can directly lead to cardiac remodeling by inducing an inflammatory response. Schisandrin B (Sch B), the active component extracted from the fruit of Schisandra chinensis (Turcz.) Baill has been shown to exhibit anti-inflammatory activity through its ability to target TLR4 and its adaptor protein, MyD88. In this study, we explored whether Sch B alleviates Ang II-induced myocardial inflammation and remodeling via targeting MyD88. Sch B significantly suppressed Ang II-induced inflammation as well as increased the expression of several genes of tissue remodeling (β-Mhc, Tgfb, Anp, α-Ska) both in vivo and in vitro. These protective effects of Sch B were due to the inhibition of recruitment of MyD88 to TLR2 and TLR4, suppressing the Ang II-induced NF-κB activation and reducing the following inflammatory responses. Moreover, the knockdown of Myd88 in cardiomyocytes abrogated the Ang II-induced increases in the production of inflammatory cytokines and expression of remodeling genes. These findings provide new evidence that the mechanism of Sch B protection was attributed to selective inhibition of MyD88 signaling. This finding could pave the way for novel therapeutic strategies for myocardial inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint Research Center on Medicine, the Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo 315700, China; Institute of Stomatology, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou…
- School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
- Joint Research Center on Medicine, the Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo 315700, China.
- Department of Pharmacology, Bashkir State Medical University, Ufa 450005, Russia.
- Joint Research Center on Medicine, the Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo 315700, China; School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China. Electronic address: yi.wa…
Förderung
- National Natural Science Foundation of China
- Russian Science Foundation
Zitieren
APA
Xu, S., Hu, C., Han, J., Luo, W., Huang, L., Jiang, Y., Samorodov, A. V., Wang, Y., & Huang, J. (2024). Schisandrin B alleviates angiotensin II-induced cardiac inflammatory remodeling by inhibiting the recruitment of MyD88 to TLRs in mouse cardiomyocytes. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112660
Vancouver
Xu S, Hu C, Han J, Luo W, Huang L, Jiang Y, et al. Schisandrin B alleviates angiotensin II-induced cardiac inflammatory remodeling by inhibiting the recruitment of MyD88 to TLRs in mouse cardiomyocytes. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112660
BibTeX
@article{Xu2024,
author = {Xu, Sujing and Hu, Chenghong and Han, Jibo and Luo, Wu and Huang, Lijiang and Jiang, Yongsheng and Samorodov, Aleksandr V and Wang, Yi and Huang, Jianxiong},
title = {Schisandrin B alleviates angiotensin II-induced cardiac inflammatory remodeling by inhibiting the recruitment of MyD88 to TLRs in mouse cardiomyocytes},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112660}
}
EUVIMED